Table 1.
The clinical characteristics of the study population
| Characteristic | No metformin use n = 705 (96%) |
Metformin use n = 32 (4%) |
p value |
|---|---|---|---|
| Diabetes rate% | 19 (2.7%) | 32 (100%) | < 0.001 *** |
| Stagea% | |||
| Early (I ~ II) | 339 (51.1%) | 16 (59.3%) | 0.3168 |
| Late (III ~ IV) | 324 (48.9%) | 11 (40.7) | |
| Histologyb% | |||
| Epithelial | 542 (81.1) | 24 (77.4) | 0.5958 |
| Other typesc | 126 (18.9) | 7 (22.6) | |
| CA-125d# | 1250 ± 273 | 767 ± 565 | 0.4109 |
| Death rate% | 239 (33.9%) | 5 (15.6%) | 0.0045 ** |
| Overall survivale§ | 57.3 ± 4.2 | 69.7 ± 22.5 | 0.0338 * |
aFIGO stage: International Federation of Gynecology and Obstetrics, surgical staging of ovarian cancer; missing value not included in statistical test
bMissing value not included in statistical test
cincluding primary peritoneal serous carcinoma (PPSC)
dbefore surgery, mean ± s.d. (U/ml)
eoverall survival months, mean ± s.d.
%calculated by Chi-square test
#calculated by Student’s t-test
§calculated by Kaplan-Meier Log-Rank test